Aardvark Therapeutics, Inc.AARDEarnings & Financial Report
Nasdaq
NextMar 31, 2026
AARD Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-17.7M
Net Profit
$-16.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.75
Aardvark Therapeutics, Inc. Q3 2025 Financial Summary
Aardvark Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-16.3M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-16.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $103000 | $594000 | $1.0M | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | N/A | N/A | N/A | $157.0M | $147.5M | $133.2M |
| Liabilities | N/A | N/A | N/A | $6.3M | $10.6M | $10.9M |
| Equity | $-36.9M | $-42.3M | $-46.2M | $150.7M | $136.9M | $122.4M |
Cash Flow
| Q1 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-2.2M | $-11.4M | $-9.8M | $-16.1M |